# Eloxx Pharmaceuticals, Inc.: overview ELOX · Nasdaq · CIK 1035354 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/elox.md) · [Financials](/companies/elox/financials.md) · [Filings](/companies/elox/filings.md) · [Insiders](/companies/elox/insiders.md) Latest reported revenue: [$0](/filings/0001144204-13-008524.md) for Q2 FY2013, three months to 2012-12-31, from the 10-Q filed Feb 14, 2013 (XBRL us-gaap:Revenues, accession 0001144204-13-008524). ## Last eight quarters | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.88)](/filings/0000950170-23-021821.md) | [(1.96)](/filings/0000950170-23-041837.md) | [(1.31)](/filings/0000950170-23-062940.md) | not reported | [(0.45)](/filings/0001193125-26-204722.md) | [(5.45)](/filings/0001193125-26-344964.md) | [(0.08)](/filings/0001193125-26-204722.md) | [(0.66)](/filings/0001193125-26-344964.md) | | Free cash flow | $k | [(6,814)](/filings/0000950170-23-021821.md) | [(2,066) d](/filings/0000950170-23-041837.md) | [(3,450) d](/filings/0000950170-23-062940.md) | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001193125-26-108687.md) | [6.4](/filings/0001193125-26-108687.md) | [0.0](/filings/0001193125-26-108687.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(38.8%)](/filings/0001193125-26-108687.md) | not reported | | Net margin | % | not reported | not reported | not reported | [(49.4%)](/filings/0001193125-26-108687.md) | not reported | | Diluted EPS | $ per share | [(38.15)](/filings/0000950170-23-011360.md) | [(16.65)](/filings/0000950170-23-011360.md) | [(6.63)](/filings/0001193125-26-108687.md) | [(0.84)](/filings/0001193125-26-108687.md) | [(0.49)](/filings/0001193125-26-108687.md) | | Free cash flow | $m | [(35.1)](/filings/0000950170-23-011360.md) | [(31.9)](/filings/0000950170-23-011360.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elox/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $5.6m | 400,000 | | New +400,000 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $5.5m | 397,160 | | New +397,160 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.1m | 78,680 | | New +78,680 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $147.2k | 10,602 | | New +10,602 | | [SEVEN GRAND MANAGERS, LLC](/funds/1909126.md) | 2026-06-30 | $138.8k | 10,000 | | New +10,000 | ## Recent filings [All 988 filings](/companies/elox/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 23:31 ET | [8-K](/filings/0001193125-26-428116.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001193125-26-428116 | | 2026-09-11 | 21:28 ET | [S-1](/filings/0001193125-26-389422.md) | Registration statement | 0001193125-26-389422 | | 2026-08-11 | 21:19 ET | [8-K](/filings/0001193125-26-345032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345032 | | 2026-08-11 | 21:02 ET | [10-Q](/filings/0001193125-26-344964.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344964 | | 2026-06-04 | 21:17 ET | [S-1/A](/filings/0001193125-26-257750.md) | Registration statement, amended | 0001193125-26-257750 | | 2026-06-01 | 20:55 ET | [S-1/A](/filings/0001193125-26-251655.md) | Registration statement, amended | 0001193125-26-251655 | | 2026-06-01 | 11:00 ET | [8-K](/filings/0001193125-26-249692.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-249692 | | 2026-05-07 | 20:57 ET | [S-1](/filings/0001193125-26-212324.md) | Registration statement | 0001193125-26-212324 | | 2026-05-05 | 01:04 ET | [10-Q](/filings/0001193125-26-204722.md) | Quarterly report, period 2026-03-31 | 0001193125-26-204722 | | 2026-05-01 | 20:05 ET | [8-K](/filings/0001193125-26-201408.md) | 5.07 Shareholder vote results | 0001193125-26-201408 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108687.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1035354 - Tickers: ELOX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.